Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Clinical trial NCT04795427 · COMPLETED
Trial details
- NCT number
- NCT04795427
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-06
- Primary completion
- 2023-05-29
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.